DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Community Living

Administration on Disabilities, The President's Committee for People With Intellectual Disabilities

AGENCY: Administration for Community Living, HHS.

ACTION: Notice.

SUMMARY: The President's Committee for People with Intellectual Disabilities (PCPID) will hold a virtual meeting for members to discuss issues related to Home and Community Based Services (HCBS) that will be a part of the Committee's Report to the President. All the PCPID meetings, in any format, are open to the public. This virtual meeting will be conducted in a discussion and presentation format with testimony from people with intellectual disabilities and other stakeholders to provide more information about their experiences with HCBS.

DATES: May 1, 2023 from 12 p.m. to 5 p.m. (EST).

Agenda: The Committee will discuss emerging issues identified by four PCPID workgroups related to HCBS: Direct support professionals, competitive integrated employment, community living, and Federal support programs. This disssion will help develop a general framework for the preparation of the PCPID Report to the President.

Additional Information: For further information, please contact Mr. David Jones, Director, Office of Intellectual Developmental Disabilities, 330 C Street SW, Switzer Building, Room 1126, Washington, DC 20201. Telephone: 202–795–7367. Fax: 202–795–7334. Email: *David.Jones@acl.hhs.gov*.

SUPPLEMENTARY INFORMATION: Stakeholder input is very important to the PCPID. Comments and suggestions, especially from people with intellectual disabilities, are welcomed. If there are comments related to HCBS or other areas that you would like to inform the PCPID, please share them through the following *ACL.gov* link: *https://acl.gov/form/pcpid?j=1555178&sfmc_sub=191090082&l=6707_HTML&u=34777761&mid=515008575&jb=0.*

Comments received by April 21st will be shared with the PCPID at the May 1st meeting.

Webinar/Conference Call: The virtual meeting is scheduled for Monday, May 1, 2023 from 12:00 p.m. to 5:00 p.m. (EST) and may end early if discussions are finished. The meeting is open to the public and will be held through a zoom meeting platform. In order for members of the public to observe the proceedings, you must register in advance at the following link: *https://www.zoomgov.com/webinar/register/WN_jjKOBx7ARW-EiJdzKgamWg.*

Background Information on the Committee: The PCPID acts in an advisory capacity to the President and the Secretary of Health and Human Services on a broad range of topics relating to programs, services, and supports for individuals with intellectual disabilities. The PCPID Charter stipulates that the Committee shall: (1) provide such advice concerning intellectual disabilities as the President or the Secretary of Health and Human Services may request; and (2) provide advice to the President and the Secretary of Health and Human Services to promote full participation of people with intellectual disabilities in their communities, such as: (A) expanding educational opportunities; (B) promoting housing opportunities; (C) expanding opportunities for competitive integrated employment; (D) improving accessible transportation options; (E) protecting rights and preventing abuse; and (F) increasing access to assistive and universally designed technologies; and (3) provide advice to the President and the Secretary of Health and Human Services to help advance racial equity and support for people with intellectual disabilities within underserved communities.

Dated: March 30, 2023.

Jill Jacobs,

Commissioner, Administration on Disabilities.

[FR Doc. 2023–06938 Filed 4–3–23; 8:45 am]

BILLING CODE 4154–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2023–N–0917]

In-Home Disposal Systems for Opioid Analgesics; Request for Information

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; request for information; establishment of a public docket.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the establishment of a docket to obtain information and comments that will assist the Agency in assessing whether in-home disposal products can be expected to meet the public health goal of mitigating the risk of nonmedical use or overdose if the Agency were to require drug manufacturers to make in-home disposal products available to patients under a risk evaluation and mitigation strategy (REMS). The Agency would like information and comments on the issues to be discussed at the public workshop convened by the National Academies of Sciences, Engineering and Medicine's (NASEM's) Forum on Drug Discovery, Development, and Translation entitled ''Defining and Evaluating In-Home Disposal Systems for Opioid Analgesics'' on June 26 and 27, 2023.

DATES: Submit either electronic or written comments, data, or information by August 28, 2023.

ADDRESSES: You may submit data and comments as follows. Please note that late, untimely filed comments will not be considered. The docket will close on August 28, 2023. The *https://www.regulations.gov* electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of August 28, 2023. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov.*
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

• *Mail/Hand delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

• For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include the Docket No. FDA–2023–N–0917 for ''In-Home Disposal Systems for Opioid Analgesics; Request for Information.'' Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

• Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ''THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov.* Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ''confidential.'' Any information marked as ''confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: *https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.*

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to *https://www.regulations.gov* and insert the docket number, found in brackets in the heading of this document, into the ''Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

FOR FURTHER INFORMATION CONTACT: Kimberly Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993–0002, 301–796–3137, *Kimberly.Lehrfeld@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION:

I. Background

Nonmedical use,[1] accidental exposure, and overdose associated with prescription opioid analgesics remain a serious problem in the United States. Patients commonly report having unused opioid analgesics after treatment of acute pain, such as pain following surgical procedures (Refs. 1 and 2). Opioid analgesics prescribed to treat chronic pain conditions can also result in unused drugs. When not properly disposed, these opioid analgesics provide opportunities for nonmedical use, accidental exposure, and overdose. Accordingly, FDA's efforts to address the opioid crisis include a focus on encouraging appropriate disposal of unused opioid analgesics (for additional information, see the **Federal Register** notice ''Providing Mail-Back Envelopes and Education on Safe Disposal With Opioid Analgesics Dispensed in an Outpatient Setting; Establishment of a Public Docket; Request for Comments'' (April 21, 2022, 87 FR 23869; Sec. I., Background (Docket No. FDA–2022–N–0165)). The Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act) (Pub. L. 115–271), signed into law on October 24, 2018, provides FDA authorities to address the opioid crisis. The SUPPORT Act authorized FDA to require through a REMS that a safe disposal packaging or safe disposal system be dispensed to certain patients with opioids or other drugs that pose a serious risk of abuse or overdose if, among other things, FDA determines that such safe disposal packaging or system may mitigate such risks and is sufficiently available (21 U.S.C. 355–1(e)(4)).

II. Topic for Public Input

This request for information is part of FDA's ongoing efforts to determine whether in-home disposal products can be expected to meet the public health goal of mitigating the risk of nonmedical use or overdose if the Agency were to require drug manufacturers to make these products available to patients under a REMS. On June 26 and 27, 2023, NASEM's Forum on Drug Discovery, Development, and Translation will hold a public workshop entitled ''Defining and Evaluating In-Home Disposal Systems for Opioid Analgesics.''

The purpose of the workshop is to provide an opportunity for stakeholders to examine in-home drug disposal systems, with a focus on removing unused opioid analgesics from the home. The workshop will feature invited presenters and discussions to explore the types of in-home drug disposal options, other than mail-back envelopes, which could be used to remove unused opioid analgesics from the home. This will include, among other things, a discussion of the scientific, behavioral, health equity, and policy considerations for assessing the safety, use, and effectiveness of in-home drug disposal options.

Workshop participants will address questions about the methods (*e.g.,* sequestration, adsorption, absorption) used in in-home disposal options for rendering opioids unavailable for nonmedical use, assuming the in-home disposal product is used as intended. In addition, workshop participants will discuss approaches and methodologies needed to evaluate the safe and correct use of in-home drug disposal options in real-world settings. Finally, workshop participants will consider potential strategies for encouraging and assessing the development and use of in-home drug disposal options. Additional meeting information, including the briefing document, agenda, and presentations, will be made available at *https://www.nationalacademies.org/our-work/advancing-regulatory-science-for-defining-and-evaluating-in-home-safe-disposal-systems-a-workshop* closer to the workshop date. FDA is seeking information and comments on the topics discussed at this meeting.

III. References

The following references are not on public display at *https://www.regulations.gov* because they have copyright restriction. Some references may be available at the website address, if listed. The references below are available for viewing only at the Dockets Management Staff (see **ADDRESSES**) between 9 a.m. and 4 p.m., Monday through Friday. FDA has verified the web addresses, as of the date this

[1] We use the term ''nonmedical'' in this document to refer to misuse of a drug, abuse of a drug, or both. ''Misuse'' is the intentional use, for therapeutic purposes, of a drug in a manner other than prescribed. ''Abuse'' is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects.

document publishes in the **Federal Register**, but websites are subject to change over time.

1. Bicket, M.C., J.J. Long, P.J. Pronovost, et al., ''Prescription Opioid Analgesics Commonly Unused After Surgery: A Systematic Review,'' *JAMA Surgery,* vol. 152(11), pp. 1066–1071, 2017, *https://doi.org/10.1001/jamasurg.2017.0831.*

2. Mallama, C.A., C.A. Greene, A.A. Alexandridis, et al., ''Patient-Reported Opioid Analgesic Use After Discharge from Surgical Procedures: A Systematic Review,'' *Pain Medicine,* vol. 23(1), pp. 22–44, 2022, *https://doi.org/10.1093/pm/pnab244.*

Dated: March 24, 2023.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2023–06650 Filed 4–3–23; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Privacy Act of 1974; System of Records

AGENCY: National Institutes of Health, Department of Health and Human Services.

ACTION: Notice of a new system of records, and rescindment of system of records notices.

SUMMARY: In accordance with the requirements of the Privacy Act of 1974, as amended, the Department of Health and Human Services (HHS) is establishing a new department-wide system of records titled Personnel (Employee and Non-Employee) Recruitment Program Records Not Covered by Other Notices, system number 09–90–2301. HHS is also rescinding two related systems of records: OGC Attorney Applicant Files, system number 09–90–0066; and Fellowship Program and Guest Researcher Records, system number 09–20–0112.

DATES: In accordance with 5 U.S.C. 552a(e)(4) and (11), this notice is applicable April 4, 2023, subject to a 30-day period in which to comment on the routine uses, described below. Please submit any comments by May 4, 2023.

ADDRESSES: The public should submit written comments, by mail or email, to Beth Kramer, HHS Privacy Act Officer, 200 Independence Ave. SW, Suite 729H, Washington, DC 20201, or *beth.krame@hhs.gov.* Comments received will be available for review at this location without redaction, unless otherwise advised by the commenter. To review comments in person, please contact Beth Kramer at *beth.kramer@hhs.gov* or (202) 690–6941.

FOR FURTHER INFORMATION CONTACT: General questions about the system of records should be submitted by mail, email, or phone to Beth Kramer, HHS Privacy Act Officer, 200 Independence Ave. SW, Suite 729H, Washington, DC 20201, or *beth.kramer@hhs.gov,* or (202) 690–6941.

SUPPLEMENTARY INFORMATION:

I. Background on New System of Records 09–90–2301

This new department-wide system of records will cover (1) recruitment and related records about individuals recruited or identified for possible recruitment for fellowship and other non-employee positions at HHS, including those who become applicants and those who do not become applicants; and (2) recruitment records about individuals recruited or identified for possible recruitment for employee positions at HHS who do not become applicants. Recruitment records about individuals who apply for employee positions at HHS are excluded, because they are covered by other system of records notices (SORNs); specifically:

- Records about Public Health Service Commissioned Corps applicants are covered by 09–40–0001 Public Health Service (PHS) Commissioned Corps General Personnel Records; and
- Records about applicants for other HHS positions are covered by OPM/GOVT–5 Recruiting, Examining, and Placement Records (however, OPM/GOVT–5 does not include records about non-applicant recruitees and recruitment candidates).

Only records for recruitment programs that retrieve records by subject individuals' names or other personal identifiers constitute Privacy Act records and are covered by the new system of records. Currently, only HHS' National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) maintain recruitment program records that need to be covered by the new system of records. A report on the new system of records was sent to the Office of Managaement and Budget (OMB) and the two Congressional committees that over see privacy, in accordance with 5 U.S.C. 552a(r).

II. Rescindment of Systems of Records 09–90–0066 and 09–20–0112

HHS is rescinding two related System of Records Notices (SORNs):

- HHS is rescinding HHS Office of the General Counsel SORN 09–90–0066, titled OGC Attorney Applicant Files, as duplicative of OPM/GOVT–5. SORN 09–90–0066 includes only records about individuals who have applied for an employment position with the HHS Office of General Counsel (OGC), and those records are entirely within the scope of OPM/GOVT–5. The records covered by SORN 09–90–0066 are still maintained by OGC, but will now be covered only by OPM/GOVT–5.
- HHS is rescinding Centers for Disease Control and Prevention SORN 09–20–0012, titled Fellowhip Program and Guest Researcher Records, HHS/CDC/PMO, as replaced by and duplicative of new department-wide SORN 09–90–2301. SORN 09–20–0012 includes only records used to recruit individuals for nonemployee positions, so those records are entirely within the scope of new SORN 09–90–2301.

Dated: March 27, 2023.

Alfred C. Johnson,

Deputy Director for Management, National Institutes of Health.

SYSTEM NAME AND NUMBER:

Personnel (Employee and Non-Employee) Recruitment Program Records Not Covered by Other Notices, 09–90–2301.

SECURITY CLASSIFICATION:

Unclassified.

SYSTEM LOCATION:

The address of each agency component responsible for this system of records is as shown in the System Manager(s) section below.

SYSTEM MANAGER(S):

The system managers are as follows:

- *For National Institutes of Health (NIH) records:* NIH Chief Officer for Scientific Workforce Diversity, 1 Center Dr., Bldg. 1, Rm. 316, Bethesda, MD 20892; Telephone: (301) 451–4296.
- *For Centers for Disease Control and Prevention (CDC) records:* Deputy Director, Division of Scientific Education and Professional Development, Mail Stop V24–5, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Atlanta, GA 30333; Email: *fellowships@cdc.gov.*

AUTHORITY FOR MAINTENANCE OF THE SYSTEM:

5 U.S.C. 1302, 2301(b)(1), 3301 *et seq.;* 42 U.S.C. 209(g) and (h), 241, 247b–8, and 284(b).

PURPOSE(S) OF THE SYSTEM:

Records about individuals recruited or considered for recruitment for employee positions at HHS are used to fulfill particular candidate sourcing requests directed at meeting specific HHS workforce recruiting goals and to respond to reporting requests.